Investing.com -- Beta Bionics, Inc. (NASDAQ:BBNX) stock fell 35% Friday after the diabetes management solutions company reported a slowdown in new patient starts despite beating revenue expectations ...

A business.com editor verified this analysis to ensure it meets our standards for accuracy, expertise and integrity. Business.com earns commissions from some listed providers. Editorial Guidelines.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Investing.com - BofA Securities downgraded Beta Bionics, Inc. (NASDAQ:BBNX) from Buy to Neutral and lowered its price target to $28.00 from $33.00 on Friday. The stock is currently trading at $31.99, ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

About Bank of America Corp. Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following ...

Learn everything you need to know about JPMorgan BetaBuilders Japan ETF (BBJP) and how it ranks compared to other funds. Research performance, expense ratio, holdings, and volatility to see if it's ...

SAN FRANCISCO (KRON) — Three out of the 10 fastest growing jobs in San Francisco involve artificial intelligence, according to data compiled by LinkedIn. Those are the findings of the job networking ...